Alterations in the intestinal microbiota can modulate mechanisms involving risk factors for cardiovascular diseases, including dyslipidemias The objective was to review the effects of probiotic supplementation on the prevention and treatment of changes to the lipid profile. The searches were run on the PubMed database, using the descriptors "probiotics and lipid profile" and "probiotics and dyslipidemia, " with publication dates restricted to 2013 to 2018. Supplementation with probiotics significantly reduced total cholesterol, LDL-c, and triglycerides and increased HDL-c. Some benefits were observed on anthropometric variables, glycemic control, oxidative stress, inflammation, and immune system. The present study suggests that probiotic supplementation should be indicated as adjunctive treatment for dyslipidemias. Further studies should be developed to clarify long-term effects, as well as the influence of probiotics in combination with drug therapy.
INTRODUCTION
The process of urbanization and the lifestyle changes that result have contributed to a substantial increase in the rates of chronic diseases, in particular of cardiovascular diseases (CVDs). These are the number one cause of death worldwide and are responsible for considerable economic losses and significant healthcare expenditure. 1 Build-up of fat, primarily visceral fat, occurs through complex interactions between genetics and environmental factors and is associated with subclinical systemic inflammation and with many different risk factors for development of CVDs. 2 Among these risk factors, hypercholesterolemia, hypertriglyceridemia, increases in the concentrations of low density lipoproteins (LDL), and reductions in the levels of high density lipoproteins (HDL) are all important targets for attempts to prevent CVDs. 3, 4 The intestinal microbiota (IM) is responsible for many different biochemical reactions and is considered an important regulator of metabolic status. 5 According to Huttenhower et al., 6 the IM is directly linked with maintenance of good health, whether intestinal or systemic. Microbiota instability, known as dysbiosis, can directly affect the emergence and resulting complications of many different diseases, especially non-transmissible chronic diseases. Changes in the composition and function of IM occur in metabolic syndrome and in CVDs, both of which are conditions in which dyslipidemia may be present.
People with hypercholesterolemia have lower bacterial diversity in their IM when compared with controls. Additionally, the profile of the microorganisms that are present is different, which suggests that IM possibly play a role in development of hypercholesterolemia. 7 Manipulation of the IM with probiotics results in several benefits for the host. 8, 9 Probiotics are already in use in human medicine, both for disease prevention and for treatment, by controlling the IM. 10 The hypocholesterolemic effects of probiotics have been investigated both in vitro and in vivo, although conflicting results have been observed. 11 Therefore, in view of the need for, and importance of, new therapeutic methods to control and improve patients' lipid profiles to help with treatment of dyslipidemia and other non-transmissible chronic diseases, the objective of this study was to review the effects of supplementation with probiotics for prevention and treatment of lipid profile abnormalities.
METHODS
This is a systematic review based on searches of the PubMed databases using a combination of the descriptors "probiotics and lipid profile" and "probiotics and dyslipidemia," with publication dates restricted to January 2013 to March 2018. Clinical trials involving subjects over the age of 18 and published in English were included in the review. The exclusion criteria were studies involving pregnant women and breastfeeding mothers.
RESULTS
A total of 28 full text articles describing clinical trials were identified. After applying the exclusion criteria and eliminating studies undertaken with pregnant women and breastfeeding mothers, removing duplicates, and reading titles, abstracts, and full texts, 14 clinical trials were selected for inclusion. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method flow diagram was used to document the details of the article selection process ( Figure 1 ). The articles selected analyzed the influence of probiotics on the lipid profile, as summarized in Table 1. 12 -25 However, not all of the studies evaluated these markers using primary methods. 15, 16, 17, 22 The genera most often administered to groups treated with probiotics were Lactobacillus, in 11 studies, and Bifidobacterium, in six studies. Other genera used were Saccharomyces, Streptococcus, Between the groups, there was a 18.3% reduction in TG and a 15.6% reduction in LDL particle size and a 21.1% increase in apo A-V (p<0.05). TG and apo A-V values were inversely correlated.
Short duration, small sample, no control of diet, and no analysis of the IM.
The authors concluded that supplementation with these strains reduced serum TG levels, and the greatest effect was observed in subjects with higher levels. and Enterococcus, in one study each. The studies were designed to evaluate the effects of probiotics on the lipid profile and other variables. Some studies allocated subjects to groups treated with probiotics in isolation and in combination with other compounds, to enable observation of their effects with and without these additives.
14,15,23 Kullisaar et al. 21 did not form distinct groups to enable such comparisons. All of the clinical trials analyzed studied small samples, with a predominance of people with dyslipidemia, and were of short duration, varying from 15 days to 12 weeks.
DISCUSSION
Supplementation with probiotics significantly reduced total cholesterol (TC), LDL cholesterol (LDL-c), 13, 18, 21, 23, 25 and triglycerides (TG) 12, 15, 18, 21, 23 and increased HDL cholesterol (HDL-c).
15,18,23
Other studies only observed significant effects when probiotics were combined with other treatments. Soy isoflavones and probiotics exhibited significant synergic effects that were not observed in groups given supplementation only. 14 Additionally, physical exercise combined with administration of a fermented probiotics product stimulated an increase in HDL-c. 17 Tonucci et al. 25 found that only the control group exhibited increases in TC, LDL-c, and TG, suggesting that probiotics had a protective effect.
A meta-analysis of 11 articles detected reductions in TC and LDL in people with normal, borderline, and high cholesterol levels. 26 Another meta-analysis found that probiotics had a positive effect on TC.
27
Because the studies were highly heterogeneous, the authors also conducted an analysis of subsets and concluded that a group with TC higher than 200 mg/dL had the best response to treatment with probiotics. 27 Subjects with hypertriglyceridemia also exhibited greater reductions in lipids. 12 Ivey et al. 20 explained that their results for lipid profile did not exhibit significant differences because the initial TC levels were lower than in other studies.
Other variables that are less frequently related to the lipid profile were also studied. Exposure of LDL-c to oxidative agents has been demonstrated in the atherosclerosis process, producing particles of oxidized LDL (oxLDL) and electronegative LDL. 28 After consumption of a fermented soy product containing isoflavones, hypercholesterolemic individuals exhibited significant reductions in electronegative LDL.
14 Findings reported by Fuentes et al. 18 and Kullisaar et al. 21 showed improvements in oxLDL. It has been observed that remnant lipoproteins (RLP) have a high atherogenic potential 29 and it was suggested that Saccharomyces boulardii reduced the quantity of RLP. 24 Several different factors affect the time needed to benefit the host's lipid profile. At 15 days, significant improvement in the lipid profile were only observed when koumiss (a fermented product made with mare's milk) was combined with physical exercise.
17
The effectiveness of physical training for prevention and control of dyslipidemia has been well established. 30 Childs et al. 15 observed a significant increase in HDL-c after 15 days of a synbiotic, when compared with placebo. In a study by Kullisaar et al., 21 beneficial effects were observed after a 4-week intervention, but it cannot be confirmed whether L. fermentum ME-3 is effective in isolation, because it was used with other compounds.
The estimated time needed to observe more definite results using probiotics in isolation appears to be 6 weeks. 23, 25 However, Fuentes et al. 18 only observed significant differences between groups at 12 weeks and they were not observed at the halfway point of the study. Additionally, it was also observed that a 4-week interval without treatment, after 12 weeks of administration, reduced the beneficial effects on the lipid profile, although they were nevertheless still greater than in the placebo group. 18 Therefore, continuous supplementation appears to be preferable, although if it is discontinued for up to 1 month, the desired effect may still be achieved.
Significant changes in anthropometric measurements were observed. Gomes et al. 19 observed additional benefits from probiotics for waist circumference, conicity index, and waist-height ratio compared with a group that was only treated with a diet. A reduction in body mass index (BMI) was observed by Bernini et al., 13 in relation to baseline values. Associations between obesity, metabolic disorders, and inflammation have been demonstrated in the literature. 31 Improvement in inflammatory markers was demonstrated in some of the studies reviewed. Patients with type 2 Diabetes mellitus (DM2) who consumed fermented milk without probiotics exhibited reductions in interleukin-10 (IL-10) (p=0.001) and a tendency to reductions in adiponectin (p=0.07), both of which have anti-inflammatory functions. This reduction was not observed in a group that did consume probiotics, providing evidence that supplementation had a protective effect.
25 Serum ultrasensitive C-reactive protein (PCR-us) and interleukin-6 (IL-6) levels were reduced in healthy volunteers (p<0.05). 21 Over 45 days of treatment with probiotics, Bernini et al. 13 observed significant reductions in tumor necrosis factor alpha (TNF-α) and IL-6. A study that employed a larger dose reported a significant reduction in PCR-us with probiotic use, whereas a group that consumed omega-3 did not exhibit the same impact. 23 Healthy IM attenuates translocation of lipopolysaccharides (LPS), inducing lower numbers of inflammatory cytokines. However, the benefits observed were not associated with improvements in the inflammatory profile. The authors suggested that patients with higher levels of inflammation would exhibit the best results. 19 A systematic review of 11 articles concluded that treatment with probiotics aids in treatment of DM2, improving many parameters related to glycemic control. 32 In the present study, it was observed that Tonucci et al. 25 reported a tendency for reductions in glycated hemoglobin (HbA1c) (p=0.06), compared with a control group, Kullisaar et al. 21 observed significant improvement in HbA1c, and Rajkumar et al. found that fasting glycemia and insulin levels were reduced in groups given supplementation with probiotics, omega-3, and both probiotics and omega-3 (p<0.05). 23 Additional effects, beyond the study objectives, were also observed. Oxidative mechanisms are involved in the processes leading to CVDs. 33 Therefore, improvements in antioxidant defenses prevent damage to macromolecules and also endothelial injury. A significant increase in glutathione peroxidase (GPx) activity was observed in a group given probiotics, in comparison with a groups that only followed a diet. This effect was not observed in relation to superoxide dismutase (SOD). 19 Individuals in a probable state of immunosenescence exhibited a positive effect on natural killer (NK) cell activity. 16 It has also been suggested that probiotics and prebiotics have a modulating effect on Th1 and Th2 lymphocytes, helping those with low Th1 activation and reducing Th2 hyperactivation in atopic diseases. 15 Studies reported dosages varying from 10 9 to 112 × 10 9 CFU/day. After 6 weeks, the largest dose demonstrated several beneficial effects and no adverse clinical effects were observed, suggesting that larger doses are safe. 23 In order to benefit the host, probiotics must have the capacity to adhere to the intestinal mucosa, overcoming the barriers imposed by the gastrointestinal tract, primarily the gastric pH, bile salts, and pancreatic enzymes. 34 In view of this, some studies tested for microorganisms in the intestine.
Evidence of the effects of probiotics show that they are strain-dependent, 35 indicating that generalization of the benefits of supplementation with probiotics should be treated with caution. As such, combining different strains appears to offer better results. 23 The mechanisms possibly involved may act in a synergic manner to improve the lipid profile. Production of bile salt hydrolases by several genera causes deconjugation of the bile salts, with lower capacity for absorption and enterohepatic recirculation and increased excretion, in addition to increased demand for cholesterol to synthesize new molecules to replace losses. Deconjugation also alters the capacity do solubilize cholesterol, reducing absorption. Furthermore, cholesterol is incorporated into cell membranes during growth of the microorganisms. Another factor described in the literature is inhibition of hepatic synthesis of cholesterol and fatty acids through production of short-chain fatty acids. 11, 36 The overall panorama indicates that the capacity for reduction of serum lipids is limited compared to treatment with statins. 37 However, probiotics offer a range of benefits, in addition to those already mentioned in this study, interacting both directly and indirectly, and possibly producing results of greater magnitude in relation to metabolic conditions and quality of life over the long term. 34, 35, 36 The divergent results of different studies may be the result of the specificity and combination of the strains employed, the doses administered, the duration of the studies, and other extraneous variables.
CONCLUSIONS
The scientific evidence indicates that there are relationships between IM and several health-related markers. Modulation of the IM with probiotics has yielded promising results. The majority of the clinical trials analyzed demonstrated that treatment with probiotics had a beneficial influence on the lipid profile. Additionally, improvements were also observed in inflammatory profile, glycemic control, body mass, and immunological markers, which are considered risk factors for development of CVDS.
This study indicates that supplementation with probiotics, as investigated in well-controlled studies, can be used as an adjuvant to traditional treatments for dyslipidemia. It is recommended that further studies be conducted, designed to identify the long-term effects and the influence of probiotics when used in combination with drug-based treatment. 
INTRODUÇÃO
O processo de urbanização e a consequente mudança no estilo de vida contribuíram para o aumento substancial de doenças crônicas, principalmente as doenças cardiovasculares (DCVs). Essas são a maior causa de mortes no mundo, gerando grandes prejuízos econômicos e no setor da saúde 1 . O acúmulo de gordura, principalmente visceral, através de complexas interações genéticas e ambientais está associado à inflamação sistêmica subclínica e aos diversos fatores de risco para o desenvolvimento de tais doenças 2 . Entre os fatores de risco, a hipercolesterolemia, a hipertrigliceridemia, o aumento da concentração de lipoproteína de baixa densidade (low-density lipoprotein, LDL) e a redução dos níveis de lipoproteína de alta densidade (high-density lipoprotein, HDL) constituem alvos importantes para a prevenção de DCV 3, 4 . Considerada importante reguladora do estado metabólico, a microbiota intestinal (MI) exerce diversas reações bioquímicas 5 . Segundo Huttenhower et al. 6 , a MI está ligada diretamente à manutenção da saúde, seja intestinal ou sistêmica. Sua instabilidade, chamada disbiose, pode alterar diretamente o desenvolvimento e as complicações de várias doenças, especialmente as doenças crônicas não transmissíveis. Na síndrome metabólica e nas DCVs, situações em que as dislipidemias podem estar presentes, existem mudanças na composição e na função da MI.
Indivíduos hipercolesterolêmicos, quando comparados aos indivíduos controles, possuem uma menor diversidade bacteriana da MI. Além disso, observa-se também uma diferença no perfil desses microrganismos, o que sugere um possível papel da MI no desenvolvimento da hipercolesterolemia 7 . A manipulação da MI com probióticos resulta em vários benefícios ao hospedeiro 8, 9 . Eles já são utilizados na medicina humana, tanto na prevenção quanto no tratamento de doenças, através do controle da MI 10 . O efeito hipocolesterolêmico dos probióticos tem sido investigado in vitro e in vivo, e controvérsias foram observadas 11 . Assim, sob a necessidade e a importância de novos métodos terapêuticos para controle e melhora do perfil lipídico a fim de auxiliar no tratamento de dislipidemias e de outras doenças crônicas não transmissíveis, o objetivo deste estudo foi revisar os efeitos da suplementação de probióticos na prevenção e no tratamento de alterações do perfil lipídico.
MÉTODOS
Trata-se de uma revisão sistemática cuja pesquisa foi realizada na base de dados PubMed utilizando a combinação dos descritores "probiotics and lipid profile" e "probiotics and dyslipidemia", no período de publicação entre janeiro de 2013 e março de 2018. Foram incluídos estudos do tipo ensaio clínico publicados na língua inglesa, com indivíduos de faixa etária acima de 18 anos. Os critérios de exclusão utilizados foram para estudos com gestantes e lactantes.
RESULTADOS
Foram encontrados 28 ensaios clínicos publicados na íntegra. Após a utilização dos critérios de exclusão para estudos realizados com gestantes e lactantes, a remoção de estudos duplicados e a leitura de títulos, resumos e artigos na íntegra, foram incluídos 14 ensaios clínicos. O fluxograma do método PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) foi utilizado para detalhar o processo de seleção dos artigos, conforme a Figura 1. 21 , foram observados efeitos benéficos com 4 semanas de intervenção, mas não é possível afirmar que o papel isolado do L. fermentum ME-3 tenha efetividade devido à adição de outros compostos.
A estimativa de tempo necessário para visualização de resultados mais expressivos com o uso exclusivo de probióticos parece ser de 6 semanas 23, 25 . Entretanto, Fuentes et al. 18 visualizaram diferenças significativas entre os grupos apenas no período de 12 semanas, fato não observado na metade do estudo. Além disso, foi observado que um intervalo de 4 semanas de interrupção de tratamento, após 12 semanas de uso, diminuiu os efeitos benéficos no perfil lipídico, que ainda assim foram maiores que no grupo placebo 18 . Assim, a suplementação contínua parece favorável e, caso interrompida em até 1 mês, consegue surtir o efeito desejável.
Alterações significativas foram observadas em relação a medidas antropométricas. Gomes et al. 19 encontraram benefício adicional dos probióticos sobre a circunferência da cintura, índice de conicidade e relação cintura-altura em comparação com o grupo que foi tratado apenas com a dieta. A redução do índice de massa corporal (IMC) foi observada por Bernini et al. 13 em relação aos valores iniciais. A associação entre obesidade, distúrbios metabólicos e inflamação é demonstrada na literatura 31 . A melhora de marcadores inflamatórios foi demonstrada em alguns estudos. Portadores de diabetes melito tipo 2 (DM2) que consumiram leite fermentado sem probióticos apresentaram redução de interleucina-10 (IL-10) (p=0,001) e tendência de redução de adiponectina (p=0,07), ambas com papel anti-inflamatório. Essa redução não foi observada no grupo que consumiu os probióticos, evidenciando efeito protetor com a suplementação 25 . Os níveis séricos de proteína C reativa ultrassensível (PCR-us) e interleucina-6 (IL-6) foram reduzidos em indivíduos saudáveis (p<0,05) 21 . Em 45 dias de tratamento com probióticos, Bernini et al. 13 revelaram redução significativa no fator de necrose tumoral alfa (TNF-α) e IL-6. O estudo que utilizou maior dose reportou diminuição significativa na PCR-us com os probióticos, enquanto o grupo que consumiu ômega-3 não alcançou o mesmo impacto 23 . A MI saudável atenua a translocação de lipopolissacarídeos (LPS), induzindo menor número de citocinas inflamatórias. Entretanto, os benefícios encontrados não foram associados com a melhora do perfil inflamatório. Os autores sugerem que sujeitos expostos a maior grau de inflamação podem obter melhores resultados 19 . Uma revisão sistemática com 11 artigos concluiu que o tratamento com probióticos auxilia no tratamento do DM2, melhorando diversos parâmetros relacionados ao controle glicêmico 32 . No presente estudo, observou-se que Tonucci et al. 25 mostraram tendência de redução na hemoglobina glicada (HbA1c) (p=0,06) em comparação com o grupo controle. Kullisaar et al. 21 observaram melhora significativa na HbA1c. A glicemia de jejum e os níveis de insulina foram reduzidos nos grupos com suplementação de probióticos, ômega-3 e ambos (p<0,05) 23 . Efeitos adicionais, além dos objetivos do estudo, foram observados. Existem mecanismos oxidativos nos processos envolvidos na DCV 33 . Assim, a melhora nas defesas antioxidantes previne os danos gerados em macromoléculas, assim como a lesão endotelial. O incremento significativo da atividade da glutationa peroxidase (GPx) foi verificado no grupo que consumiu os probióticos em detrimento do que consumiu apenas a dieta. Isso não foi verificado com a superóxido dismutase (SOD) 19 . Indivíduos em provável imunossenescência sofreram interferência positiva na atividade de células natural killer (NK) 16 . É sugerido um papel modulador do probiótico e do prebiótico estudados nos linfócitos Th1 e Th2, auxiliando aqueles com baixa ativação de Th1 e diminuindo a hiperativação de Th2 em doenças atópicas 15 . Os estudos reportaram doses entre 10 9 e 112 × 10 9 UFC/dia. A maior dose demonstrou, em 6 semanas, vários efeitos benéficos sem a observância de alterações clínicas adversas, sugerindo o uso seguro para maiores doses 23 . Para propiciar benefícios ao hospedeiro, os probióticos devem ter capacidade de aderir à mucosa intestinal, sobrepondo as barreiras impostas pelo trato gastrintestinal, principalmente o pH gástrico, os sais biliares e as enzimas pancreáticas 34 . Nessa perspectiva, alguns estudos avaliaram a presença dos microrganismos no intestino 14, 15, 23, 25 . Os efeitos evidenciados pelos probióticos são caracterizados como cepa-dependente 35 , indicando que a generalização dos benefícios dessa suplementação com probióticos deve ser feita com cautela. Assim, a combinação de diferentes cepas parece propiciar melhores resultados 23 . Possíveis mecanismos podem atuar de forma sinérgica em favor da melhora do perfil lipídico. A produção de hidrolases de sais biliares por vários gêneros resulta em desconjugação dos sais biliares, em menor capacidade de absorção para recirculação entero-hepática e maior excreção, em requerimento aumentado do colesterol para síntese de novas moléculas a fim de repor a perda. A desconjugação também altera a capacidade de solubilização do colesterol, reduzindo a absorção. Além disso, ocorre incorporação do colesterol nas membranas celulares durante o crescimento dos microrganismos. A inibição da síntese hepática do colesterol e ácidos graxos através da produção de ácidos graxos de cadeia curta é outro fator descrito na literatura 11, 36 . O panorama indica capacidade limitada de redução dos lipídios séricos em comparação ao tratamento com estatinas 37 . Entretanto, os probióticos propiciam diversos benefícios, além dos supracitados neste estudo, interagindo de maneira direta e indireta, possivelmente promovendo resultados com maior magnitude em condições metabólicas e qualidade de vida em longo prazo 34, 35, 36 . A divergência entre os estudos pode ser oriunda da especificidade e combinação das cepas utilizadas, da dose administrada, da duração do estudo, além de outras variáveis intervenientes.
CONCLUSÃO
As evidências científicas indicam relação da MI com vários marcadores relacionados à saúde. A modulação da MI com probióticos tem apresentado resultados promissores. A maioria dos ensaios clínicos analisados demonstrou influência benéfica no perfil lipídico através do tratamento com probióticos. Além disso, também foram observadas melhoras no perfil inflamatório, controle glicêmico, massa corporal e marcadores imunológicos, considerados fatores de risco para o desenvolvimento de DCV.
O presente estudo indica a suplementação de probióticos, previamente investigados em estudos bem controlados, como coadjuvante no tratamento tradicional das dislipidemias. Sugere-se a realização de estudos futuros com a finalidade de esclarecer os efeitos de longo prazo, assim como a influência dos probióticos em associação com o tratamento medicamentoso.
